Clinical Trial

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of icovamenib in participants with Type 2 Diabetes who are not achieving glycemic targets despite antihyperglycemic medications.
Protocol Amendment History 3 changes
notable Primary completion moved earlier: 2027-06 -> 2027-03 2026-08-08
minor Completion pushed: 2027-07 -> 2027-09 2026-08-08
notable Trial sites expanded: 7 -> 15 locations 2026-04-09
Trial Details
NCT Number NCT07502495
Lead Sponsor Biomea Fusion Inc.
Conditions Type 2 Diabetes
Enrollment 60 participants
Start Date 2026-03-27
Primary Completion 2027-03 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-07